Louis Pascarella has been named the company’s Chief Executive Officer and a member of Innocoll’s Board of Directors. Pascarella, who will retain his current role of President, succeeds Rich Fante, who is stepping down after a successful tenure as CEO and has agreed to serve as an adviser to Innocoll’s Board for at least the next year to ensure a smooth transition.
Read More

About Innocoll
Innocoll is a specialty pharmaceutical company committed to improving the status quo and finding answers to unmet needs

XARACOLL® (bupivacaine HCl) Implant
Our lead product, XARACOLL, was approved by the U.S. Food and Drug Administration in August 2020